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Background: The recognition of nodular melanoma is clinically challenging, and the diagnostic ac-
curacy of dermoscopy and confocal microscopy is lower than for superficial spreading melanoma.
Objectives: To test a management strategy consisting in the excision of any nodular lesion that cannot 
be confidently and precisely classified as a benign tumor after clinical and dermoscopic examination.
Methods: Clinical and dermoscopic images of excised nodular lesions were retrospectively collected 
and evaluated. The evaluators were asked to record the level of diagnostic confidence for each lesion, 
by declaring if they were confident or doubtful about the given diagnosis. The NNE (number needed 
to excise) value was used to evaluate the efficacy of the proposed method.
Results: A total of 1,319 excised nodular lesions formed the study set. The NNE for any malignancy 
was 3.9 (634/164), while the NNE for melanoma was 13.2 (634/48). NNE for hypo and amelanotic 
melanoma was 27.3 (327/12).
Conclusions: Excising doubtful nodular lesions seems to be an effective management strategy not 
to miss nodular melanoma, resulting in an acceptable rate of unnecessary excision of benign lesions.
ABSTRACT
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will are not routinely performed at our referral centers, but 
all excisions are performed to rule out malignancy. The inclu-
sion criteria for the current study were the availability of 
clinical and dermoscopic images of a nodular lesion that was 
excised and histopathologically diagnosed. Nodularity was 
evaluated on clinical images, in which a ruler was available. 
Pure nodular and flat palpable lesions with a nodular com-
ponent were included. We did not select lesions based on the 
histopathologic diagnosis; thus, both benign and malignant 
lesions were included for evaluation. The study period was 
2008 to 2014. Clinical images were acquired using a high-
resolution digital camera. Dermoscopic images were captured 
using non-polarized dermoscopes (DermLite Foto, 3Gen LLC, 
Dana Point, CA).
All images were evaluated by two residents in dermatol-
ogy with an average expertise in dermoscopy. The evaluators 
were blinded to the final histopathologic diagnosis. The 
presence of pigmentation was assessed on the dermoscopic 
images, and a lesion was classified as pigmented when pig-
mentation was involving 50% or more of the lesion surface, 
hypopigmented when pigmentation was present in less than 
50% of the lesion surface, and amelanotic when no pigmenta-
tion was detected at all. The evaluators were asked to provide 
a diagnosis based on the clinical and dermoscopic aspects of 
the lesion. To serve the main aim of our study, the evaluators 
were also asked to record the level of diagnostic confidence 
for each lesion, by declaring if they were confident or doubt-
ful about the given diagnosis. The NNE (number needed to 
excise) value was used to evaluate the efficacy of the proposed 
method [20-22]. This was obtained by dividing the total 
number of doubtful lesions excised to the number of those 
histopathologically proven to be malignant. NNE values were 
calculated for all malignancies (NNE total) and for melanoma 
diagnosis in particular.
Results
In all, 1,319 excised nodular lesions formed the study set. Of 
these, 747 (56.6%) were malignant and 572 (43.4%) were 
benign. The study sample included: hemangioma (27; 2.0%), 
angiocheratoma (3; 0.2%), angioleiomioma (1; 0.1%), clear 
cell acanthoma (5; 0.4%), angiosarcoma (2; 0.2%), basal 
cell carcinoma (283; 21.4%), squamous cell carcinoma (205; 
15.5%); Merkel cell carcinoma (3; 0.2%), cylindroma (2; 
0.2%), epidermal cyst (20; 1.5%), dermatofibroma (60; 4.5%), 
pyogenic granuloma (24; 1.8%), Kaposi sarcoma (12; 0.9%), 
melanoma (199; 15.0%), metastasis from internal tumors (2; 
0.2%), melanocytic nevi (342; 25.9%), other benign lesions 
(88; 6.7%), and other malignant lesions (41; 3.1%).
On clinical-dermoscopic evaluation, 685 of 1,319 lesions 
(51.9%) were assessed as surely malignant and 634 (48.1%) 
as doubtful. Of 685 lesions clinically/dermoscopically judged 
Introduction
Nodular melanoma (NM) is a very aggressive subtype of 
melanoma lacking a significant superficial spreading phase 
and, consequently, being thicker at diagnosis as compared 
with other melanoma subtypes [1]. Although NM accounts 
only for 9 to 15% of melanomas, it is responsible for 43% of 
melanoma deaths, according to a population-based study in 
Australia [2]. Because of its peculiar clinical characteristics, 
the ABCD clinical criteria are usually of no help for NM 
recognition [3-5]. The tumor typically develops as a rapidly 
growing, firm papule or nodule. These clinical characteristics 
have been summarized by the EGF rule (Elevation, Growth, 
Firmness), which has been proposed to facilitate the recogni-
tion of NM by patients and clinicians [6,7]. The introduc-
tion of noninvasive diagnostic tools in dermatology, such 
as dermoscopy and confocal microscopy, has significantly 
improved melanoma diagnostic accuracy [5,8-18]. Despite 
these advances, the recognition of NM remains a challenge, 
because its clinical and dermoscopic features may be similar 
to benign nodular lesions, such as hemangioma, pyogenic 
granuloma, seborrheic keratosis, dermatofibroma, and der-
mal nevi. Several studies have investigated the accuracy of 
dermoscopic criteria in the diagnosis of NM, reporting sen-
sitivity, specificity, and predictive values lower than those for 
superficial spreading melanoma (SSM) [8]. Reflectance confo-
cal microscopy (RCM), a recently introduced diagnostic tool 
allowing skin evaluation at a quasi histologic level, has been 
tested for the diagnosis of nodular lesions in a retrospective 
study [17]. However, the use of RCM is limited by its cost 
and availability. Moreover, the presence of hyperkeratosis and 
ulceration may prevent the deeper evaluation of the tumor 
structures and render RCM of limited value in NM [17].
When taking into consideration the limitations of clinical, 
dermoscopic and confocal diagnosis, a practical management 
strategy has been suggested so as not to miss NM [8,19]. 
According to this approach, any nodular lesion that cannot 
be confidently and precisely classified as a benign tumor 
after clinical and dermoscopic examination should be his-
topathologically diagnosed [19]. However, one might argue 
that applying this strategy would result in a high number 
of excisions of benign lesions. The aim of this study was to 
evaluate the effectiveness of this strategy, by evaluating the 
number needed to excise (NNE) when applying the rule of 
excising any doubtful nodular lesion.
Material and Methods
Clinical and dermoscopic images of excised nodular lesions 
were retrospectively collected from the databases of two 
pigmented lesion clinics in Naples and Reggio Emilia, Italy. 
As a general rule, excision for cosmetic concern or patient 
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doubtful and histopathologically malignant. In the subgroup 
of hypo- or amelanotic lesions, the NNE for any malignancy 
was 2.8 (327/116). A subset of 33 melanomas consisted of 
hypo- or amelanotic lesions. Of these, 12 lesions were judged 
doubtful; thus, the NNE for hypo and amelanotic melanoma 
was 27.3 (327/12).
The majority of histopathologically benign lesions that 
were judged to be doubtful under clinical and dermoscopic 
examination were melanocytic nevi (279 lesions, 44.0%), 
including Spitz nevus (102; 16.1%), compound nevus (86; 
13.6%), dermal nevus (24; 3.8%), blue nevus (16; 2.5%), 
Clark nevus (15; 2.4%), congenital nevus (14; 2.2%), and 22 
(3.5%) other nevi, not specified. Dermatofibroma accounted 
for 50 (7.9%) of the benign doubtful lesions, whereas 32 
(5.0%) were angiomas, 22 (3.5%) pyogenic granulomas, and 
15 (2.4%) epidermal cysts.
as surely malignant, 583 were indeed malignant histopatho-
logically (85.1%), and 102 (14.9%) were histopathologically 
benign. Of 634 clinically/dermoscopically doubtful lesions, 
164 (25.9%) were histopathologically malignant, including 
48 melanomas. Thus, the NNE for any malignancy was 3.9 
(634/164), while the NNE for melanoma was 13.2 (634/48).
Two hundred eighty-three BCC were included in the study 
set, and of these 238 were judged “sure malignant,” and 45 
clinically doubtful. Two hundred five SCC were included in 
the study set, and 154 were judged clinically “sure malignant,” 
and 34 clinically doubtful. Of the 199 melanomas, 151 were 
clinically “sure malignant,” and 48 were clinically doubtful.
Regarding pigmentation, 755 lesions were hypo or amela-
notic and, of these, 509 were malignant. Three hundred 
twenty-seven lesions were hypo or amelanotic and clinically/
dermoscopically doubtful. Of these, 116 lesions were judged 
Figure 1. Clinical presentation of 4 nodular lesions excised to rule out melanoma. (a) A red-purple-to-black nodule, arising on the leg of a 
72-year-old woman. The patient reported recent onset and sudden change in color. The lesion was excised and histopathologically diagnosed 
as angioma. (b) A large amelanotic nodule, arising on the leg of 80-year-old woman. Three smaller papules were visible in the surrounding 
skin (white arrows). The patient was unaware of the time duration of the lesions. A biopsy was taken, and a final diagnosis of clear cell 
acanthoma with satellites was given. (c) An 8 mm diameter amelanotic, ulcerated nodule arising on the abdomen of a 40-year-old man. The 
lesion was noticed three months before and was rapidly growing in size. Histopathologic examination revealed a melanoma 2.5 mm Breslow 
thickness. (d) A 6 mm nodule (white arrow) arising on the chest of a 64-year-old man with a prior history of multiple primary melanomas. 
Color variegation and presence of central bluish hue prompted excision. Histopathology revealed a dermal nevus. [Copyright: ©2017 Mos-
carella et al.]
4 Research  |  Dermatol Pract Concept 2017;7(3):1
benign lesions are excised to find one malignancy [20-22]. 
The NNE depends on both the expertise of the clinician and 
the prevalence of the disease. Usually, NNE values for mela-
noma diagnosis vary between 4 and 30, with lower values 
achieved in specialized or referral centers [23]. Our results 
are in line with previous studies, confirming that diagnosing 
nodular melanoma can be challenging.
When considering malignant lesions overall, including 
BCC, SCC, and others, an NNE value of 3.9 was achieved. 
In simple words, when applying the rule of excising doubtful 
nodular lesions, 1 out of 4 will be proven to be malignant. 
This result highlights that applying this approach results in 
an acceptable number of excisions of benign lesions.
Within the group of clinically doubtful benign lesions, 
the great majority were melanocytic nevi (44%), with Spitz, 
compound and dermal nevi accounting for 16.1%, 13.6 and 
3.8% of excisions, respectively. Apart from Spitz nevi that are 
well-known simulators of melanoma, compound, and dermal 
nevi are usually easy to recognize both clinically and dermo-
Discussion
When facing nodular lesions, clinicians are asked to provide 
one of two mutually exclusive management recommenda-
tions, namely, excision or “no action” [19]. Follow-up of 
nodular lesions is not an option, because of the possibility of 
missing a nodular melanoma, which may result in worsened 
prognosis given the high growth rate of the tumor [1,19]. 
To address this problem, a practical management strategy 
has been suggested, namely to recommend surgical excision 
of all nodular lesions for which a confident and specific 
diagnosis of a benign tumor is not feasible after clinical and 
dermoscopic examination [19]. However, one could argue 
that applying this rule in daily practice could result in a high 
number of unnecessary excisions of benign lesions.
Our results suggest that the aforementioned strategy is 
effective, resulting in an NNE of 13.2 for the diagnosis of 
melanoma. The number needed to excise is a value indicating 
the accuracy of a screening strategy, measuring how many 
Figure 2. Corresponding dermoscopy image of the four excised nodular lesions (thrombosed hemangioma, clear cell acanthoma, nodular 
melanoma and dermal nevus). (a) Asymmetric lesion, with red-to-purple background, purple globules and two areas of structureless blue 
pigmentation. (b) A symmetric amelanotic lesion, with multiple dotted vessels in a chain-like distribution, the so-called “string of pearls.” 
(c) An amelanotic nodule displaying central ulceration, scaling, and peripheral short linear vessels over a pink background. (d) Asymmetric 
nodular lesion, with brown globules and short linear vessels. A central area of structureless white-blue pigmentation is visible. [Copyright: 
©2017 Moscarella et al.]
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scopically. However, sometimes their morphologic character-
istics might not allow a confident diagnosis. As shown by our 
results, such morphologically atypical nevi should be removed 
when applying the rule of excising doubtful nodular lesions. 
(Figures 1 and 2) However, given that the NNE remains abso-
lutely acceptable, sacrificing a small number of nevi to avoid 
missing nodular melanoma seems a reasonable compromise.
With a value of 2.8 lesions to excise to find one malig-
nancy, our results highlight that the rule of excising doubtful 
nodular lesions is particularly effective for hypo- or non-
pigmented tumors. Among nonmelanocytic lesions, the most 
problematic in our series were dermatofibroma, hemangioma, 
and pyogenic granuloma, accounting for 16.4% of doubtful 
lesions. This confirms that benign nonmelanocytic lesions 
represent a consistent proportion of the lesions to be consid-
ered in the differential diagnosis of nodular melanoma.
One limitation of our study was the retrospective design, 
which did not allow us to evaluate prospectively the factors 
prompting excision of a given lesion. However, as a general 
rule, at our referral centers, all excisions are performed to 
rule out malignancy.
In conclusion, excising doubtful nodular lesions seems 
to be an effective management strategy not to miss nodular 
melanoma, resulting in an acceptable rate of unnecessary 
excision of benign lesions.
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